Terms: = Leukemia AND CEBPA, CEBP, 1050, C/EBP-alpha, P49715 AND Treatment
256 results:
1. Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies.
Ip BBK; Wong ATC; Law JHY; Au CH; Ma SY; Chim JCS; Liang RHS; Leung AYH; Wan TSK; Ma ESK
Sci Rep; 2024 Mar; 14(1):6400. PubMed ID: 38493200
[TBL] [Abstract] [Full Text] [Related]
2. Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses.
Severens JF; Karakaslar EO; van der Reijden BA; Sánchez-López E; van den Berg RR; Halkes CJM; van Balen P; Veelken H; Reinders MJT; Griffioen M; van den Akker EB
Leukemia; 2024 Apr; 38(4):751-761. PubMed ID: 38360865
[TBL] [Abstract] [Full Text] [Related]
3. Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
Zhang T; Zhang Y; Zhou M; Zhang Z; Bao X; Wen L; Feng Y; Li X; Zhai M; Liu X; Zeng Z; Wu X; Chen S
Br J Haematol; 2024 Apr; 204(4):1402-1413. PubMed ID: 38327115
[TBL] [Abstract] [Full Text] [Related]
4. Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance.
Mishra R; Zokaei Nikoo M; Veeraballi S; Singh A
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203655
[TBL] [Abstract] [Full Text] [Related]
5. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G; McCloskey J; Griffiths EA; Yee KWL; Zeidan AM; Al-Kali A; Deeg HJ; Patel PA; Sabloff M; Keating MM; Zhu N; Gabrail NY; Fazal S; Maly J; Odenike O; Kantarjian H; DeZern AE; O'Connell CL; Roboz GJ; Busque L; Buckstein R; Amin H; Randhawa J; Leber B; Shastri A; Dao KH; Oganesian A; Hao Y; Keer HN; Azab M; Savona MR
Lancet Haematol; 2024 Jan; 11(1):e15-e26. PubMed ID: 38135371
[TBL] [Abstract] [Full Text] [Related]
6. LILRB3 Modulates Acute Myeloid leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy.
Mai S; Hodges A; Chen HM; Zhang J; Wang YL; Liu Y; Nakatsu F; Wang X; Fang J; Xu Y; Davidov V; Kang K; Pingali SR; Ganguly S; Suzuki M; Konopleva M; Prinzing B; Zu Y; Gottschalk S; Lu Y; Chen SH; Pan PY
Cancer Res; 2023 Dec; 83(24):4047-4062. PubMed ID: 38098451
[TBL] [Abstract] [Full Text] [Related]
7. Assessment of 2022 European leukemiaNet risk classification system in real-world cohort from China.
Chen E; Jiao C; Yu J; Gong Y; Jin D; Ma X; Cui J; Wu Z; Zhou J; Wang H; Su B; Ge J
Cancer Med; 2023 Dec; 12(24):21615-21626. PubMed ID: 38098254
[TBL] [Abstract] [Full Text] [Related]
8. Insight into the mechanism of AML del(9q) progression: hnRNP K targets the myeloid master regulators cebpa (C/EBPα) and SPI1 (PU.1).
Rahn K; Abdallah AT; Gan L; Herbrich S; Sonntag R; Benitez O; Malaney P; Zhang X; Rodriguez AG; Brottem J; Marx G; Brümmendorf TH; Ostareck DH; Ostareck-Lederer A; Crysandt M; Post SM; Naarmann-de Vries IS
Biochim Biophys Acta Gene Regul Mech; 2024 Mar; 1867(1):195004. PubMed ID: 38008244
[TBL] [Abstract] [Full Text] [Related]
9. Genomic Mutation Profiles of Patients with Acute Myeloid leukemia in Korea: a Single-Center Experience.
Han E; Ryu S; Kim D; Koh EH; Byun JH; Lee DH
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948498
[TBL] [Abstract] [Full Text] [Related]
10. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.
Williams LS; Williams KM; Gillis N; Bolton K; Damm F; Deuitch NT; Farhadfar N; Gergis U; Keel SB; Michelis FV; Panch SR; Porter CC; Sucheston-Campbell L; Tamari R; Stefanski HE; Godley LA; Lai C
Transplant Cell Ther; 2024 Mar; 30(3):255-267. PubMed ID: 37913908
[TBL] [Abstract] [Full Text] [Related]
11. TET2 lesions enhance the aggressiveness of cebpa-mutant acute myeloid leukemia by rebalancing GATA2 expression.
Heyes E; Wilhelmson AS; Wenzel A; Manhart G; Eder T; Schuster MB; Rzepa E; Pundhir S; D'Altri T; Frank AK; Gentil C; Woessmann J; Schoof EM; Meggendorfer M; Schwaller J; Haferlach T; Grebien F; Porse BT
Nat Commun; 2023 Oct; 14(1):6185. PubMed ID: 37794021
[TBL] [Abstract] [Full Text] [Related]
12. Mutations in the bZip region of the cebpa gene: A novel prognostic factor in patients with acute myeloid leukemia.
Rivera JC; Nuñez D; Millar E; Ramirez K; Chandía M; Aguayo C
Int J Lab Hematol; 2023 Dec; 45(6):833-838. PubMed ID: 37621152
[TBL] [Abstract] [Full Text] [Related]
13. Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients.
Chen M; Zeng Z; Li X; Qin W; Cai X; Chen S; Lu X
Int J Lab Hematol; 2023 Dec; 45(6):899-907. PubMed ID: 37519024
[TBL] [Abstract] [Full Text] [Related]
14. Cytogenetically Normal Acute Myeloid Leukaemia at a Single Centre in South Africa.
Jenkins N; Blanshard LA; Stone M; Verburgh E; Oosthuizen J; Shires K
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):397-406. PubMed ID: 37363984
[TBL] [Abstract] [Full Text] [Related]
15. [Research Progress of m6A Demethylase FTO and Its Inhibitors in Acute Myeloid leukemia --Review].
Fang ZH; Zheng SY; Feng WY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):902-906. PubMed ID: 37356958
[TBL] [Abstract] [Full Text] [Related]
16. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid leukemia].
Cao L; Jiang ZQ; Liu WJ; Sun Q; Zhu Y; Li JY; Qian SX; Hong M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
[TBL] [Abstract] [Full Text] [Related]
17. [Impact of
Li RQ; Wen XL; Zhang XL; Dong CX; Wang MF; Liu XX; Huang YJ; Tan YH; Chang JM; Zhang RJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):628-632. PubMed ID: 37356918
[TBL] [Abstract] [Full Text] [Related]
18. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
[TBL] [Abstract] [Full Text] [Related]
19. Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer's disease.
Stevenson M; Varghese R; Hebron ML; Liu X; Ratliff N; Smith A; Turner RS; Moussa C
J Neuroinflammation; 2023 May; 20(1):116. PubMed ID: 37194065
[TBL] [Abstract] [Full Text] [Related]
20. Melatonin Can Enhance the Effect of Drugs Used in the treatment of leukemia.
Lomovsky AI; Baburina YL; Fadeev RS; Lomovskaya YV; Kobyakova MI; Krestinin RR; Sotnikova LD; Krestinina OV
Biochemistry (Mosc); 2023 Jan; 88(1):73-85. PubMed ID: 37068876
[TBL] [Abstract] [Full Text] [Related]
[Next]
